Why the study?
The study was conducted to provide an update regarding the safety profile of tinzaparin prescribed as prophylactic or therapeutic regimens for venous thromboembolism in special populations, including cancer and renal impairment.
Does tinzaparin have a safe bleeding and bioaccumulation profile in cancer patients and patients with renal impairment?
Population
Cancer patients and patients with renal impairment
Comparison
Tinzaparin regimens vs vitamin K antagonists
Design
Systematic review of prospective studies
Authors
Loading...
Tinzaparin may be considered in cancer and renal-impaired patients; leaves open need for randomized trials before changing practice.
Does tinzaparin have a safe bleeding and bioaccumulation profile in cancer patients and patients with renal impairment?
Tinzaparin can be safely used without dose adjustment in patients with severe renal impairment (creatinine clearance > 20 ml/min) and exhibits lower rates of clinically relevant nonmajor bleeding compared to vitamin K antagonists in cancer patients.
Vathiotis et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: